
Coronavirus Disease 2019 (COVID-19)


Situation Report – 135

Timor-Leste



*Data as reported on 18 January 2022





HIGHLIGHTS

- Since the last edition of the weekly situation report, the Ministry of Health (MoH) reported
 18 new case of COVID-19, 2 recovery and 0 death. The number of new cases and deaths remains low.
- The Ministry of Finance Timor-Leste and KOICA officially signed the Project Agreement to implement the project "Say No to 5S in Schools" Starvation, Soil-transmitted Helminthiasis, Skin diseases, Smoking, and Sugary/alcoholic drinks. This project will be implemented by WHO and WFP in collaboration with the Ministry of Health and Ministry of Education. Under the 5S programme, WHO will focus on all primary and pre-secondary school-age children with the objective to have school-age children free of priority diseases and major risk factors including malnutrition or wasting through Primary Health Care Package provision under the scheme of WHO's Health Promoting School.
- NHL participated the WHO Global Influenza Surveillance and Response System, and External Quality Assessment Project (WHO GISRS EQAP) for Influenza and SARS CoV-2 from

Hong Kong during 2021. The results from NHL Timor-Leste are 100% correct for both influenza and for SARS CoV-2.

- WHO Timor-Leste supported the Ministry of Health in collaboration with WHO SEAR and leading dengue experts from All India Institute of Medical Sciences (AIIMS), National Vector Borne Disease Control Programme (NVBDCP), and Municipality Corporation of Delhi (MCD) conducted 2-days training on clinical management of dengue for clinicians and nurses from HNGV and CHCs from Dili Municipality. The training aims to orient the key clinicians and Nurses from HNGV and CHC Dili on most updated Dengue Clinical Case Management Algorithms based on the current Dengue Clinical Management Guidelines.
- As the number of dengue cases increasing in the country, poses a threat to the community.
 WHO handed over first batch of dengue RDT Kits and larvicidal to the Ministry of Health to help curb the outbreak in the country. The dengue RDT kits can be used for 10,000 tests.
- WHO continues to extend logistic support to Pillar 2 Ministry of Health to sensitize communities on COVID-19 vaccine and COVID-19 prevention messages through door-to-door campaign and vehicle miking.
- WHO teams and the immunization consultants deployed in 10 municipalities continues to be on the ground supporting the vaccination teams in all municipalities to increase the COVID-19 vaccination coverage and routine immunization in the country.

EPIDEMIOLOGICAL UPDATES

1. Distribution of cases and deaths by municipalities

Distribution of newly reported, recovered, and active cases by municipalities, as of 11 January 2022)


Municipality	New case (5-11 Jan. 2022)	Last 7-day % change (case)*	Cumulative case	New recovered (5-11 Jan. 2022)	Cumulative recovered	New death (5-11 Jan. 2022)	Cumulative death	Active Cases (11 Jan. 2022)
Aileu								
Ainaro								
Baucau								
Bobonaro								
Covalima								
Dili								
Ermera								
Lautem								
Liquica								
Manatuto								
Manufahi								
RAEOA								
Viqueque								
TOTAL								

^{*}Change in new COVID-19 cases as compared with the previous 7 days

2. Number of test and test positivity rates

CASE MANAGEMENT

Cases remain low in Dili Isolation Centers. There are currently no COVID-19 cases admitted to critical care isolation center (Lahane and Vera Cruz). The last case discharged from Lahane Isolation Center was on 29 December 2021. Overall, cases remain low throughout the country.



Isolation totals for mild cases are noted in the chart, which shows the total number of people admitted to isolation centres and auto-isolation (at home) in 12 municipalities compared to Dili. Throughout Timor-Leste, number of cases on isolation has been steadily decreased.

VACCINATION

At the time of writing this report (18/01/2022 morning), in total, 1,230,900 COVID-19 vaccine doses comprising 668,912 first doses (coverage 83.8% among population aged 18 years and above and 19.8% among the population aged 12 years to <18 years), 557,044 second doses (coverage 69.9% among population aged 18 years and above and 16.3% among the population aged 12 years to <18 years), 4387 (coverage 0.6% among population aged 18 years) booster doses were administered in Timor-Leste. The breakdown of the number of doses administered and coverage by vaccine product and vaccine dose is illustrated in Table 1.

Table 1: Number of COVID-19 vaccine doses administered and coverage in Timor-Leste by vaccine product and dose as of 10:00hrs 18/01/2022




Figure 1: Coverage of COVID-19 vaccination among population aged 18 years and above by municipality in Timor-Leste as of 10:00hrs 18/01/2022




Table 2: Total number of individuals vaccinated with all the vaccine products (AstraZeneca, Sinovac, and Pfizer) and AEFI by sex by district in Timor-Leste as of 10:00 hrs 18/01/2022

			AEFI										
Municipality		First Dose		S	econd Dose	e	В	ooster Dos	e	Male	Female	Total	
	Male	Female Total		Male	Female	Total	Male	Male Female		iviale	remale	TOLAI	
Dili	120,740	102,737	223,477	108,668	95,624	204,292	3,102	1,842	4,944	14	26	40	
Aileu	12,885	12,318	25,203	9,830	9,581	19,411	-	-	-	1	1	2	
Ainaro	14,315	13,894	28,209	10,855	10,874	21,729	1	-	-	0	0	0	
Baucau	30,578	31,115	61,693	25,586	25,927	51,513	1	-	-	0	0	0	
Bobonaro	22,011	21,867	43,878	15,249	14,787	30,036	1	-	-	4	6	10	
Covalima	19,355	19,535	38,890	15,520	15,397	30,917	-	-	-	7	6	13	
Ermera	27,086	25,039	52,125	20,022	18,732	38,754	1	-	-	0	0	0	
Lautem	14,132	15,371	29,503	11,183	12,850	24,033	-	-	-	2	0	2	
Liquica	17,876	18,183	36,059	14,443	14,673	29,116	-	-	-	0	1	1	
Manatuto	12,247	11,597	23,844	9,174	8,831	18,005	-	-	-	2	0	2	
Manufahi	14,674	13,848	28,522	11,514	10,994	22,508	-	-	-	1	2	3	
Viqueque	20,180	21,289	41,469	17,468	18,847	36,315	•	-	-	6	0	6	
ZEEMS (Oecusse)	17,525	18,515	36,040	14,847	15,568	30,415	-	-	-	0	0	0	
Total (without Dili)	222,864	222,571	445,435	175,691	177,061	352,752	-	-	-	23	16	39	
Total (Timor-Leste)	343,604	325,308	668,912	284,359	272,685	557,044	3,102	1,842	4,944	37	42	79	

Figure 2: Weekly progress of COVID-19 vaccination in Timor-Leste as of 10:00 hrs 18/01/2022




Table 3. Number of individuals among population aged 12 years to <18 years and above* vaccinated with Pfizer vaccine and coverage by district in Timor-Leste as of 10:00hrs 18/01/2022

			First [Oose	Second Dose					
Municipality	12to <18y Population	12 to <18y Students	12 to <18y Non- students	Total	Coverage	12 to <18y Students	12 to <18y Non- students	Total	Coverage	
Dili	41,822	35,968	34	36,002	86.1%	29,589	16	29,605	70.8%	
	- (2007)									
Aileu	7,770	-	-	-	0.0%	-	-	-	0.0%	
Ainaro	10,253	-	-	-	0.0%	-	-	-	0.0%	
Baucau	18,189	-	1/2	-	0.0%	_	_	-	0.0%	
Bobonaro	14,466		-		0.0%	-	17	-	0.0%	
Covalima	9,729	-	- 2	-	0.0%	-	-	-	0.0%	
Ermera	20,564	-	-	-	0.0%	-	-	-	0.0%	
Lautem	10,447	-	- 42	-	0.0%	-	-	-	0.0%	
Liquica	11,137	-	-	-	0.0%	-	-	-	0.0%	
Manatuto	7,108	-	- 2	-	0.0%	-	-	-	0.0%	
Manufahi	8,267	-	-	-	0.0%	-	-	-	0.0%	
Viqueque	11,490	-	- 42	-	0.0%	-	-	-	0.0%	
ZEEMS (Oecusse)	10,565	-	-	-	0.0%	-	-	-	0.0%	
Total (without Dili)	139,985	-	-	-	0.0%	-	-	-	0.0%	
Total (Timor-Leste)	181,807	35,968	34	36,002	19.8%	29,589	16	29,605	16.3%	

^{*}Based on 2021 population projections

Total Vaccinated (both doses) 65,607

Table 4. Number of individuals among population aged 18 years and above vaccinated with AstraZeneca and Sinovac vaccines and coverage by district in Timor-Leste as of 10:00hrs 18/01/2022

			Number V	accinated an	d Coverage	as of 18/01/	2022 10.00	hrs amon	Eligible P	opulation (1	18y and ab	ove)* with As	traZeneca,	Sinovac, an	d Pfizer (bo	ooster dose) \	/accines				
	Elig	Eligible Population			Number vaccinated & Coverage																
Municipality	High Risk	18 59y no	Effection.	First Dose					Second Dose						Booster Dose						
	Groups (20% Pop.)		High Risk Groups (20% Pop.)	Coverage	18-59y no comorbidity (80% Pop.)	Coverage	Total	Coverage	High Risk Groups (20% Pop.)	Coverage	18-59y no comorbidity (80% Pop.)	Coverage	Total	Coverage	High Risk Groups (20% Pop.)	Coverage	18-59y no comorbidity (80% Pop.)	Coverage	Total	Coverage	
Dili	29,980	183,822	213,902	53,626	178.9%	133,849	72.8%	187,475	87.7%	34,359	114.6%	140,328	76.3%	174,687	81.7%	2662	1.2%	2275	1.1%	4937	2.3%
	10000			1/2																	
Alleu	6,292	24,943	31,235	12,928	205.5%	12,275	49.2%	25,203	80.7%	10,506	167.0%	8,905	35.7%	19411	62.1%	0	0.0%	0	0.0%	0	0.0%
Ainaro	7,410	27,726	35,136	6,709	90.5%	21,500	77.5%	28,209	80.3%	4,965	67.0%	16,764	60.5%	21729	61.8%	0	0.0%	0	0.0%	0	0.0%
Baucau	18,141	55,175	73,316	17,498	96.5%	44,195	80.1%	61,693	84.1%	13,145	72.5%	38,368	69.5%	51513	70.3%	0	0.0%	0	0.0%	0	0.0%
Bobonaro	13,268	43,476	56,744	11,073	83.5%	32,805	75.5%	43,878	77.3%	7,315	55.1%	22,721	52.3%	30036	52.9%	0	0.0%	0	0.0%	0	0.0%
Covalima	8,725	31,503	40,228	10,209	117.0%	28,681	91.0%	38,890	96.7%	7,284	83.5%	23,633	75.0%	30917	76.9%	0	0.0%	0	0.0%	0	0.0%
Ermera	14,350	60,793	75,143	10,922	76.1%	41,203	67.8%	52,125	69.4%	6,434	44.8%	32,320	53.2%	38754	51.6%	0	0.0%	0	0.0%	0	0.0%
Lautem	8,455	27,963	35,418	8,485	100.4%	21,018	75.2%	29,503	81.0%	6,838	80.9%	17,195	61.5%	24033	66.0%	0	0.0%	0	0.0%	0	0.0%
Liquica	9,588	35,597	45,185	9,113	95.0%	26,946	75.7%	36,059	79.8%	6,836	71.3%	22,280	62,6%	29116	64.4%	0	0.0%	0	0.0%	0	0.0%
Manatuto	6,701	21,718	28,419	6,848	102.2%	16,995	78.3%	23,844	83.9%	4,698	70.1%	13,307	61.3%	18005	63.4%	0	0.0%	0	0.0%	0	0.0%
Manufahl	7,595	25,766	33,361	9,636	126.9%	18,886	73.3%	28,522	85.5%	9,138	120.3%	13,370	51.9%	22508	67.5%	0	0.0%	0	0.0%	0	0.0%
Viqueque	11,034	32,905	43,939	12,533	113.6%	28,936	87.9%	41,469	94.4%	10,500	95.2%	25,815	78.5%	36315	82,6%	0	0.0%	0	0.0%	0	0.0%
ZEEMS (Oecusse)	9,408	32,534	41,942	11,607	123.4%	24,433	75.1%	35,040	85.9%	8,053	85.6%	22,362	68.7%	30,415	72.5%	0	0.0%	0	0.0%	0	0.0%
Total (without Dill)	120,967	420,098	541,065	127,561	105.5%	317,874	75.7%	445,435	82.3%	95,712	79.1%	257,040	61.2%	352,752	65.2%	0	0.0%	0	0.0%	0	0.0%
Total (Timor-Leste)	150,947	603,920	754,867	181,187	120.0%	451,723	74.80%	632,910	83.8%	130,071	86.2%	397,368	65.8%	527,439	69.9%	2662	0.4%	2275	0.3%	4937	0.7%

Based on 2021 population projections. Population with Comorbidity 12.5% among 30-59y based on 2016 DHS data

High Kisk Groups (20% of the popyulation) - Healthcare staff, other front line staff, aged 60y and above, and 18-50y with comorbidity

Total Vaccinated (all doses)

1,165,286

(Total No. of third Doses -

7

18-50y with no comorbidity (80% of the population)

SITUATION ANALYSIS

- The number of new cases has doubled during the current reporting period as compared with the previous one. Meanwhile, the volume of test and test positivity rate have also increased.
- Looking at the reported cases closely, most are international travellers returning to
 Timor-Leste. Meanwhile, there are also cases from the sentinel sites at the health care
 facilities. According to the laboratory, some of the samples demonstrated S gene target
 failure (SGTF). We are still waiting for the confirmation of genome sequencing results
 from Australia laboratory, though these are likely to be Omicron variant.
- Currently Timor-Leste is experiencing the dengue outbreak in the capital region.
 Hospital beds are fully occupied by dengue patients. If the expected Omicron
 transmission wave comes during the next several weeks, there would pose double
 burden to the health systems. All level of health facilities must act and be prepared.

CURRENT CONCERN

Latest update on Omicron variant (7 Jan. 2022)

- The overall risk related to Omicron remains very high for a number of reasons. First,
 the global risk of COVID-19 remains very high overall. Second, current data indicate
 that Omicron has a significant growth advantage over Delta, leading to rapid spread
 in the community. The rapid increase in cases will lead to an increase in
 hospitalizations, may pose overwhelming demands on health care systems and lead
 to significant morbidity, particularly in vulnerable populations.
- The overall threat posed by Omicron largely depends on four key questions: (i) how
 transmissible the variant is; (ii) how well vaccines and prior infection protect against
 infection, transmission, clinical disease and death; (iii) how virulent the variant is
 compared to other variants; and (iv) how populations understand these dynamics,
 perceive risk and follow control measures, including public health and social
 measures (PHSM).
- For more information, please read the technical brief with the link below.

(Source: Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States)

AVAILABLE RESOURCES

- For public and professionals on prevention, treatment, and vaccination etc.
- WHO Recommendations for COVID-19 Related Decisions

WHO Free Courses in Tetum – OpenWHO.org

COVID-19 INFORMATION AND MEDIA QUERIES

- The MoH has established a hotline number 119 for COVID-19 on which people can call to get any COVID-19 related information.
- Additionally, <u>MoH Facebook page</u> provides timely updates on COVID-19 developments in the country.
- WHO Timor-Leste through its <u>Facebook page</u> and <u>Twitter handle</u> also disseminates information on preventive measures, questions and answers, myth-busters and latest updates on COVID-19 globally and nationally.
- For media queries and interviews requests can be sent to hasane@who.int